Bolt Biotherapeutics, Inc. Stock Price, News & Analysis

Bolt Biotherapeutics (NASDAQ: BOLT) has announced a key opinion leader (KOL) conference call and webcast scheduled for May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET. The event will feature Dr. Ecaterina Dumbrava from MD Anderson Cancer Center, who will discuss the Phase 1 dose-escalation clinical study results of BDC-3042 previously presented at the AACR Annual Meeting in April 2025.

During the call, Bolt's management team will also provide updates on BDC-3042 partnering plans, BDC-4182 clinical development, and first quarter 2025 financial results. A Q&A session will follow the presentations. The event will be accessible via webcast, with a replay available on the company's investor relations website.

Bolt Biotherapeutics has unveiled promising preclinical results for its next-generation Boltbody™ ISACs targeting CEA and PD-L1 at the AACR Annual Meeting 2025. The company's CEA-targeted ISAC demonstrated complete responses in mice and showed good tolerance in non-human primates (NHPs) up to 15 mg/kg.

The CEA ISAC features a novel human antibody that targets CEACAM-5, commonly found in gastrointestinal cancers. Key findings include enhanced phagocytosis of CEA-positive tumor cells and stimulation of immune-activating cytokines.

The PD-L1 ISAC showed remarkable results by:

• Directly activating and reprogramming PD-L1-expressing myeloid cells
• Achieving complete regressions in models resistant to conventional treatments
• Demonstrating favorable safety profiles in NHP studies

Both ISACs showed potential for durable responses through immunological memory, supporting their use in combination with standard-of-care therapies.

Bolt Biotherapeutics (BOLT) announced promising results from its Phase 1 dose-escalation study of BDC-3042, a novel immunotherapy for cancer treatment, at the AACR Annual Meeting 2025. The study enrolled 17 patients across seven dose cohorts with various tumor types.

Key findings include:

• BDC-3042 was well-tolerated up to 10 mg/kg q2w with no dose-limiting toxicities
• No drug-related serious adverse events or treatment discontinuations reported
• Most common drug-related adverse events: fatigue, flatulence, and nausea (12% each)
• Demonstrated favorable pharmacokinetics and biological activity
• Showed anti-tumor activity, including an unconfirmed partial response in NSCLC
• 80% of evaluable patients achieved stable disease or better

The company is now seeking partnership opportunities to advance BDC-3042's development, particularly focusing on NSCLC and post-immunotherapy settings.

Bolt Biotherapeutics (BOLT) announced it will present data from its Phase 1 dose-escalation clinical study of BDC-3042 at the AACR Annual Meeting in Chicago (April 25-30, 2025). BDC-3042 is a pioneering agonist antibody targeting dectin-2, specifically designed for patients with advanced cancers including non-small cell lung cancer (NSCLC).

The company will showcase three poster presentations: the first-in-human dose-escalation study results of BDC-3042, presented by Dr. Ecaterina Dumbrava from MD Anderson Cancer Center, and two preclinical studies featuring their Boltbody™ ISAC technology targeting CEA and PD-L1. These presentations will highlight advancements in their immunotherapy pipeline for treating various cancers including colorectal, pancreatic, and lung tumors.

Bolt Biotherapeutics (NASDAQ: BOLT) reported its Q4 and full-year 2024 financial results, highlighting key developments in its cancer immunotherapy pipeline. The company maintains a strong cash position of $70.2 million, expected to fund operations through mid-2026.

Two major programs are advancing: BDC-4182, targeting claudin 18.2 for gastric cancer, is scheduled to begin clinical trials in Q2 2025. The BDC-3042 Phase 1 trial has completed enrollment in its highest dose cohort with no dose-limiting toxicities, with results expected in Q2 2025.

Financial highlights for 2024 include: collaboration revenue of $7.7 million, R&D expenses of $57.5 million (down from $61.5M in 2023), and G&A expenses of $18.5 million (reduced from $22.5M in 2023). The company reported an operational loss of $73.0 million for the full year.

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company focused on cancer immunotherapies, has announced its participation in two major healthcare conferences this March. The company will deliver a presentation at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 3:10 p.m. EST. Additionally, Bolt's management team will engage in one-on-one meetings at the Leerink Partners Global Healthcare Conference on March 10, 2025.

Bolt Biotherapeutics (BOLT) announced that Caprin-1 is the target of their worldwide co-development collaboration with Toray Industries. The partners are developing a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) targeting Caprin-1, which is applicable to multiple solid tumor types.

Under the agreement, Toray provides proprietary antibodies targeting Caprin-1, including TRK-950, while Bolt contributes proprietary linker-payloads from its Boltbody™ ISAC platform. Caprin-1 is a tumor-specific antigen highly expressed on solid tumors with minimal presence in normal tissues, and contributes to tumor growth and metastases. Toray's TRK-950 antibody is currently in Phase 2 development for Gastric cancer.

Bolt Biotherapeutics (BOLT) reported Q3 2024 financial results, highlighting progress in its cancer immunotherapy programs. The company advanced to the highest dose level in BDC-3042's Phase 1 trial and presented updated preclinical data for BDC-4182 at SITC. Q3 revenue was $1.1 million, down from $2.5 million in Q3 2023. R&D expenses decreased to $13.8 million from $15.0 million, while G&A expenses reduced to $3.8 million from $5.8 million. The company reported an operational loss of $16.4 million. With $84.4 million in cash, funding is expected to last through mid-2026.

Bolt Biotherapeutics (BOLT) presented updated preclinical data for BDC-4182, their next-generation Boltbody™ ISAC targeting claudin 18.2, and findings from Phase 1 dose-escalation trial of BDC-1001 at SITC. BDC-4182 showed superior efficacy compared to claudin 18.2 ADCs in preclinical studies, demonstrating anti-tumor activity across various models and acceptable safety in non-human primates. The company plans to initiate clinical trials in 2025. The Phase 1 BDC-1001 trial revealed that greater immune activation was associated with clinical benefit, particularly in patients with high HER2 antigen expression, supporting the development of next-generation ISACs with enhanced immune activation.